0.877

0.76% 0.0066

Pre-market: .88 0.003 +0.34%

Reviva Pharmaceuticals Holdings Inc (RVPH)

Overview News Price History Option Chain Financials Discussions Forecast

Reviva Pharmaceuticals Holdings Inc stock is traded at $0.877, with a volume of 278.24K. It is up +0.76% in the last 24 hours and down -13.17% over the past month. Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Previous Close:

$0.8704

Open:

$0.89

24h Volume:

278.24K

Relative Volume:

0.28

Market Cap:

$35.43M

Revenue:

Net Income/Loss:

$-37.65M

P/E Ratio:

-0.5251

EPS:

-1.67

Net Cash Flow:

$-24.14M

1W Performance:

+15.68%

1M Performance:

-13.17%

6M Performance:

-25.68%

1Y Performance:

-69.76%

1-Day Range:

$0.8502

$0.898

1-Week Range:

$0.77

$0.9156

52-Week Range:

$0.485

$4.28

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Name

Reviva Pharmaceuticals Holdings Inc

Sector

Healthcare (1153)

Industry

Biotechnology (664)

Phone

(408) 501-8881

Address

10080 N WOLFE ROAD, CUPERTINO

Employee

Twitter

Next Earnings Date

2025-03-31

Latest SEC Filings

RVPH's Discussions on Twitter

Compare RVPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVPH Reviva Pharmaceuticals Holdings Inc	0.877	35.43M	0	-37.65M	-24.14M	-1.67
VRTX Vertex Pharmaceuticals Inc	503.50	126.09B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	568.91	64.01B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	629.51	36.63B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	257.19	30.64B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.77	27.24B	3.81B	-644.79M	-669.77M	-6.24

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-20-23	Initiated	ROTH MKM	Buy
Jun-08-23	Initiated	The Benchmark Company	Speculative Buy
Jan-24-22	Initiated	H.C. Wainwright	Buy

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News

Apr 29, 2025

Reviva to Participate in the Citizens Life Sciences Conference - GlobeNewswire

Apr 29, 2025

Reviva Pharma CEO Takes Center Stage: Key Updates Coming at Major Life Sciences Conference - Stock Titan

Apr 29, 2025

Apr 28, 2025

Gaining Ground: Reviva Pharmaceuticals Holdings Inc (RVPH) Closes Lower at 0.86, Down -4.98 - DWinneX

Apr 28, 2025

Market Update: American Rebel Holdings Inc (AREB) Sees Negative Movement, Closing at 3.85 - DWinneX

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 26, 2025

D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World

Apr 26, 2025

Apr 24, 2025

Reviva Pharmaceuticals Holdings Inc Inc. (RVPH) Price Performance: The Role of Supply and Demand - investchronicle.com

Apr 24, 2025

Reviva to Present Late-Breaking Poster on the RECOVER - GlobeNewswire

Apr 24, 2025

Major Phase 3 Breakthrough: Reviva Unveils 12-Month Schizophrenia Treatment Data at ASCP 2025 - Stock Titan

Apr 24, 2025

Investing in Reviva Pharmaceuticals Holdings Inc (RVPH) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com

Apr 24, 2025

Apr 21, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 21, 2025

Apr 19, 2025

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com

Apr 04, 2025

Apr 03, 2025